Collect

Bone marrow or leukemic blood sample in an EDTA (purple-top) tube.



Formalin-fixed, paraffin embedded (FFPE) tissue: a minimum of freshly cut 6 20-um scrolls or 10 slides can be shipped overnight to the laboratory. It would be best to cut and ship Monday to be delivered to us on Tuesday. The laboratory may reach out if additional material is required in case of extraction failure. Please note: unlike the other specimens in which isolated RNA is extracted, only Total Nucleic Acid (DNA and RNA) is extracted from FFPE tissue.

Specimen Preparation

See "Collect" section above.

Storage/Transport Temperature

Room temperature

Performed

Monday-Friday 9:00am - 4:00pm

Volume Required

3-5 mL

Minimum Required

1.5 mL

Phlebotomy Draw

Yes

Performed

Monday-Friday 9:00am - 4:00pm

Methodology

Targeted Capture and anchored multiplex PCR (for fusions) followed by Massively Parallel Sequencing. MLPA, Real Time PCR, or aCGH may be used when needed. Copy number variations (CNVs) of these genes are evaluated by analyzing NGS data. These CNVs are confirmed by MLPA, Real Time PCR, or aCGH when necessary. Certain genes or exons may not be evaluated for gross copy number variations, such as genes with no known gross deletion/duplication mutations, or genes or exons with pseudogenes or highly homologous sequences in the genome.

Reported

21 days

Synonyms

  • Heme Panel, Fusion
  • COHEM
  • ABL1, ASXL1, ASXL2, ATRX, BCL11B, BCL6, BCOR, BCORL1, BRAF, BRINP3, CALR, CBL, CCND3, CD79A, CD79B, CDC25C, CDKN2A, CDKN2B, CEBPA, CREBBP, CRLF2, CSF1R, CSF3R, CTCF, DDX41, DNM2, DNMT1, DNMT3A, DOT1L, EBF1, EED, ELANE, EP300, EPOR, ERG, ESR1, ETNK1, ETS1, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GATA3, HNRNPK, HRAS, IDH1, IDH2, IKZF1, IKZF3, IL7R, JAK1, JAK2, JAK3, KDM6A, KIT, KMT2A, KMT2C, KMT2D, KRAS, LEF1, LYL1
  • MAP2K1, MPL, MSH2, MSH6, MYB, MYD88, NF1, NOTCH1, NPM1, NRAS, NSD1, NSD2 (WHSC1), NT5C2, PAX5, PDGFRA, PHF6, PIK3R1, PRPF40B, PRPF8, PTEN, PTPN11, RAD21, RB1, RELN, RPL10, RTEl1, RUNX1, SETBP1, SETD2, SF1, SF3A1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, STAT3, SUZ12, TAL1, TCF3, TERT, TET2, TINF2, TLX1, TLX3, TP53, U2AF1, U2AF2, UBA2, USH2A, USP7, WT1, ZRSR2
  • ABL1, ABL2, AKT3, ALK, ARHGAP26, AXL, BCL2, BCL6, BCR, BRAF, BRD3, BRD4, CAMTA1, CBFB, CCNB3, CCND1, CIC, CRFL2, CSF1R, DNAJB1, DUSP22, EGFR, EPC1, EPOR, ERG, ESR1, ESRRA, ETV1, ETV4, ETV5, ETV6, EWSR1, FGFR1, FGFR2, FGFR3, FGR, FOXO1, FUS, GLI1, GLIS2, HMGA2, IL2RB, IL3, INSR, JAK2, JAZF1, KMT2A, MALT1, MAML2, MAST1, MAST2, MEAF6, MECOM, MET, MKL1, MKL2, MSMB, MUSK, MTB, MYC
  • NCOA2, NOTCH1, NOTCH2, NRG1, NTRK1, NTRK2, NTRK3, NUMBL, NUP214, NUP98, NUT, PAX5, PDGFB, PDGFRA, PDGFRB, PICALM, PIK3CA, PKN1, PLAG1, PPARG, PRKACA, PRKCA, PRKCB, PTK2B, RAF1, RARA, RBM15, RELA, RET, ROS1, RSPO2, RSPO3, RUNX1, RUNX1T1, SS18, STAT6, TAF15, TAL1, TCF12, TCF3, TERT, TFE3, TFEB, TFG, THADA, TMPRSS2, TSLP, TYK2, USP6, YWHAE

LIS Mnemonic

COHEM

Performed By

Division of Genomic Diagnostics

Available STAT

No

Clinical Features

The CHOP Hematological Cancer Panel v2.2 utilizes next-generation sequencing technology to simultaneously analyze a panel of genes known to be associated with hematological malignancies. Hematological malignancies results from accumulation of multiple genomic alterations that lead to aberrant hematopoietic proliferation and differentiation. These genomic alterations are important diagnostic, prognostic, and therapeutic biologic markers. The CHOP Hematological Cancer Panel test can provide important genomic information regarding tumor development and progression, which facilitates more accurate disease diagnosis, risk stratification, and therapeutic decision. Ninety-nine genes known to be associated with cancer predisposition are analyzed using Next Generation Sequence (NGS) technology. All coding exons of the 118 genes and 5 base pairs of 5' and 3' flanking intronic sequences are analyzed. Certain known intronic mutations of these genes are also evaluated. Clinically actionable or potentially actionable variants detected by NGS are confirmed by Sanger sequencing or other methodologies. 110 fusion gene partners are analyzed for approximately 600 known fusions using anchored multiplex PCR technology followed by NGS. The technology allows detecting novel fusions associated with genes in this panel. Fusions are confirmed by FISH or Real Time PCR when necessary. This panel does not detect fusions not included in this panel. The panel should not be used for detecting residual fusions at present time. 

Molecular Testing Notes

Sequenced genes: ABL1, ASXL1, ASXL2, ATRX, BCL11B, BCL6, BCOR, BCORL1, BRAF, BRINP3, CALR, CBL, CCND3, CD79A, CD79B, CDC25C, CDKN2A, CDKN2B, CEBPA, CREBBP, CRLF2, CSF1R, CSF3R, CTCF, DDX41, DNM2, DNMT1, DNMT3A, DOT1L, EBF1, EED, ELANE, EP300, EPOR, ERG, ESR1, ETNK1, ETS1, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GATA3, HNRNPK, HRAS, IDH1, IDH2, IKZF1, IKZF3, IL7R, JAK1, JAK2, JAK3, KDM6A, KIT, KRAS, LEF1, LYL1, KMT2A, KMT2C, KMT2D, MAP2K1, MPL, MSH2, MSH6, MYB, MYD88, NF1, NOTCH1, NPM1, NRAS, NSD1, NT5C2, NUDT15, PAX5, PDGFRA, PHF6, PIK3R1, PRPF40B, PRPF8, PTEN, PTPN11, RAD21, RB1, RELN, RPL10, RETEI1, RUNX1, SETBP1, SETD2, SF1, SF3A1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, STAT3, SUZ12, TAL1, TCF3, TERT, TET2, TINF2, TLX1, TLX3, TP53, TPMT, U2AF1, U2AF2, UBA2, USH2A, USP7, WHSC1, WT1, ZRSR2 Fusion partner genes: ABL1, ABL2, AKT3, ALK, ARHGAP26, AXL, BCL2, BCL6, BCR, BRAF, BRD3, BRD4, CAMTA1, CBFB, CCNB3, CCND1, CIC, CRFL2, CSF1R, DNAJB1, DUSP22, EGFR, EPC1, EPOR, ERG, ESR1, ESRRA, ETV1, ETV4, ETV5, ETV6, EWSR1, FGFR1, FGFR2, FGFR3, FGR, FOXO1, FUS, GLI1, GLIS2, HMGA2, IL2RB, IL3, INSR, JAK2, JAZF1, KMT2A, MALT1, MAML2, MAST1, MAST2, MEAF6, MECOM, MET, MKL1, MKL2, MSMB, MUSK, MTB, MYC, NCOA2, NOTCH1, NOTCH2, NRG1, NTRK1, NTRK2, NTRK3, NUMBL, NUP214, NUP98, NUT, PAX5, PDGFB, PDGFRA, PDGFRB, PICALM, PIK3CA, PKN1, PLAG1, PPARG, PRKACA, PRKCA, PRKCB, PTK2B, RAF1, RARA, RBM15, RELA, RET, ROS1, RSPO2, RSPO3, RUNX1, RUNX1T1, SS18, STAT6, TAF15, TAL1, TCF12, TCF3, TERT, TFE3, TFEB, TFG, THADA, TMPRSS2, TSLP, TYK2, USP6, YWHAE

CPT Codes

81455
Collection

Collect

Bone marrow or leukemic blood sample in an EDTA (purple-top) tube.



Formalin-fixed, paraffin embedded (FFPE) tissue: a minimum of freshly cut 6 20-um scrolls or 10 slides can be shipped overnight to the laboratory. It would be best to cut and ship Monday to be delivered to us on Tuesday. The laboratory may reach out if additional material is required in case of extraction failure. Please note: unlike the other specimens in which isolated RNA is extracted, only Total Nucleic Acid (DNA and RNA) is extracted from FFPE tissue.

Specimen Preparation

See "Collect" section above.

Storage/Transport Temperature

Room temperature

Performed

Monday-Friday 9:00am - 4:00pm

Volume Required

3-5 mL

Minimum Required

1.5 mL

Phlebotomy Draw

Yes
Ordering

Performed

Monday-Friday 9:00am - 4:00pm

Methodology

Targeted Capture and anchored multiplex PCR (for fusions) followed by Massively Parallel Sequencing. MLPA, Real Time PCR, or aCGH may be used when needed. Copy number variations (CNVs) of these genes are evaluated by analyzing NGS data. These CNVs are confirmed by MLPA, Real Time PCR, or aCGH when necessary. Certain genes or exons may not be evaluated for gross copy number variations, such as genes with no known gross deletion/duplication mutations, or genes or exons with pseudogenes or highly homologous sequences in the genome.

Reported

21 days

Synonyms

  • Heme Panel, Fusion
  • COHEM
  • ABL1, ASXL1, ASXL2, ATRX, BCL11B, BCL6, BCOR, BCORL1, BRAF, BRINP3, CALR, CBL, CCND3, CD79A, CD79B, CDC25C, CDKN2A, CDKN2B, CEBPA, CREBBP, CRLF2, CSF1R, CSF3R, CTCF, DDX41, DNM2, DNMT1, DNMT3A, DOT1L, EBF1, EED, ELANE, EP300, EPOR, ERG, ESR1, ETNK1, ETS1, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GATA3, HNRNPK, HRAS, IDH1, IDH2, IKZF1, IKZF3, IL7R, JAK1, JAK2, JAK3, KDM6A, KIT, KMT2A, KMT2C, KMT2D, KRAS, LEF1, LYL1
  • MAP2K1, MPL, MSH2, MSH6, MYB, MYD88, NF1, NOTCH1, NPM1, NRAS, NSD1, NSD2 (WHSC1), NT5C2, PAX5, PDGFRA, PHF6, PIK3R1, PRPF40B, PRPF8, PTEN, PTPN11, RAD21, RB1, RELN, RPL10, RTEl1, RUNX1, SETBP1, SETD2, SF1, SF3A1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, STAT3, SUZ12, TAL1, TCF3, TERT, TET2, TINF2, TLX1, TLX3, TP53, U2AF1, U2AF2, UBA2, USH2A, USP7, WT1, ZRSR2
  • ABL1, ABL2, AKT3, ALK, ARHGAP26, AXL, BCL2, BCL6, BCR, BRAF, BRD3, BRD4, CAMTA1, CBFB, CCNB3, CCND1, CIC, CRFL2, CSF1R, DNAJB1, DUSP22, EGFR, EPC1, EPOR, ERG, ESR1, ESRRA, ETV1, ETV4, ETV5, ETV6, EWSR1, FGFR1, FGFR2, FGFR3, FGR, FOXO1, FUS, GLI1, GLIS2, HMGA2, IL2RB, IL3, INSR, JAK2, JAZF1, KMT2A, MALT1, MAML2, MAST1, MAST2, MEAF6, MECOM, MET, MKL1, MKL2, MSMB, MUSK, MTB, MYC
  • NCOA2, NOTCH1, NOTCH2, NRG1, NTRK1, NTRK2, NTRK3, NUMBL, NUP214, NUP98, NUT, PAX5, PDGFB, PDGFRA, PDGFRB, PICALM, PIK3CA, PKN1, PLAG1, PPARG, PRKACA, PRKCA, PRKCB, PTK2B, RAF1, RARA, RBM15, RELA, RET, ROS1, RSPO2, RSPO3, RUNX1, RUNX1T1, SS18, STAT6, TAF15, TAL1, TCF12, TCF3, TERT, TFE3, TFEB, TFG, THADA, TMPRSS2, TSLP, TYK2, USP6, YWHAE

LIS Mnemonic

COHEM

Performed By

Division of Genomic Diagnostics

Available STAT

No

Clinical Features

The CHOP Hematological Cancer Panel v2.2 utilizes next-generation sequencing technology to simultaneously analyze a panel of genes known to be associated with hematological malignancies. Hematological malignancies results from accumulation of multiple genomic alterations that lead to aberrant hematopoietic proliferation and differentiation. These genomic alterations are important diagnostic, prognostic, and therapeutic biologic markers. The CHOP Hematological Cancer Panel test can provide important genomic information regarding tumor development and progression, which facilitates more accurate disease diagnosis, risk stratification, and therapeutic decision. Ninety-nine genes known to be associated with cancer predisposition are analyzed using Next Generation Sequence (NGS) technology. All coding exons of the 118 genes and 5 base pairs of 5' and 3' flanking intronic sequences are analyzed. Certain known intronic mutations of these genes are also evaluated. Clinically actionable or potentially actionable variants detected by NGS are confirmed by Sanger sequencing or other methodologies. 110 fusion gene partners are analyzed for approximately 600 known fusions using anchored multiplex PCR technology followed by NGS. The technology allows detecting novel fusions associated with genes in this panel. Fusions are confirmed by FISH or Real Time PCR when necessary. This panel does not detect fusions not included in this panel. The panel should not be used for detecting residual fusions at present time. 

Molecular Testing Notes

Sequenced genes: ABL1, ASXL1, ASXL2, ATRX, BCL11B, BCL6, BCOR, BCORL1, BRAF, BRINP3, CALR, CBL, CCND3, CD79A, CD79B, CDC25C, CDKN2A, CDKN2B, CEBPA, CREBBP, CRLF2, CSF1R, CSF3R, CTCF, DDX41, DNM2, DNMT1, DNMT3A, DOT1L, EBF1, EED, ELANE, EP300, EPOR, ERG, ESR1, ETNK1, ETS1, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GATA3, HNRNPK, HRAS, IDH1, IDH2, IKZF1, IKZF3, IL7R, JAK1, JAK2, JAK3, KDM6A, KIT, KRAS, LEF1, LYL1, KMT2A, KMT2C, KMT2D, MAP2K1, MPL, MSH2, MSH6, MYB, MYD88, NF1, NOTCH1, NPM1, NRAS, NSD1, NT5C2, NUDT15, PAX5, PDGFRA, PHF6, PIK3R1, PRPF40B, PRPF8, PTEN, PTPN11, RAD21, RB1, RELN, RPL10, RETEI1, RUNX1, SETBP1, SETD2, SF1, SF3A1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, STAT3, SUZ12, TAL1, TCF3, TERT, TET2, TINF2, TLX1, TLX3, TP53, TPMT, U2AF1, U2AF2, UBA2, USH2A, USP7, WHSC1, WT1, ZRSR2 Fusion partner genes: ABL1, ABL2, AKT3, ALK, ARHGAP26, AXL, BCL2, BCL6, BCR, BRAF, BRD3, BRD4, CAMTA1, CBFB, CCNB3, CCND1, CIC, CRFL2, CSF1R, DNAJB1, DUSP22, EGFR, EPC1, EPOR, ERG, ESR1, ESRRA, ETV1, ETV4, ETV5, ETV6, EWSR1, FGFR1, FGFR2, FGFR3, FGR, FOXO1, FUS, GLI1, GLIS2, HMGA2, IL2RB, IL3, INSR, JAK2, JAZF1, KMT2A, MALT1, MAML2, MAST1, MAST2, MEAF6, MECOM, MET, MKL1, MKL2, MSMB, MUSK, MTB, MYC, NCOA2, NOTCH1, NOTCH2, NRG1, NTRK1, NTRK2, NTRK3, NUMBL, NUP214, NUP98, NUT, PAX5, PDGFB, PDGFRA, PDGFRB, PICALM, PIK3CA, PKN1, PLAG1, PPARG, PRKACA, PRKCA, PRKCB, PTK2B, RAF1, RARA, RBM15, RELA, RET, ROS1, RSPO2, RSPO3, RUNX1, RUNX1T1, SS18, STAT6, TAF15, TAL1, TCF12, TCF3, TERT, TFE3, TFEB, TFG, THADA, TMPRSS2, TSLP, TYK2, USP6, YWHAE
Result Interpretation
Administrative

CPT Codes

81455